Janssen Pharmaceutica and Iktos have partnered to develop applications for small molecule drug discovery using Iktos' AI-based virtual design technology and Janssen's expertise in AI-based prediction of small-molecule activities. The companies will work together on a number of projects including the development of new drugs targeting cancer or other diseases that are difficult to treat with existing drugs.
Janssen Pharmaceutica and Iktos have partnered to develop applications for small molecule drug discovery using Iktos' AI-based virtual design technology and Janssen's expertise in AI-based prediction of small-molecule activities. Meanwhile, Iktos will release a beta version of its software as a service (SaaS) platform Makya this year, while Janssen has developed AI-based methods that can replace human tasks, a move that will speed up drug discoveries.